Clinical application of fetal sex determination using cell-free fetal DNA in pregnant carriers of X-linked genetic disorders

18Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

As the first step in prenatal diagnosis of X-linked genetic disorders, chorionic villus sampling (CVS) for fetal sex determination is generally performed at 11-13 weeks of gestation. However, as the procedure-related miscarriage rate of CVS is 0.5-1.0%, non-invasive methods such as PCR of cell-free fetal DNA (cff-DNA) in maternal plasma are preferable. Here, we determined fetal sex at 9-12 weeks of gestation using PCR of cff-DNA in three pregnant carriers of Duchenne muscular dystrophy. The fetal sex was accurately determined in all three cases, as confirmed by ultrasound and amniocentesis at 16 weeks (for the two female fetuses) and CVS at 12 weeks (for the one male fetus). This procedure could avoid unnecessary CVS in female fetuses. © 2011 The Japan Society of Human Genetics All rights reserved.

Cite

CITATION STYLE

APA

Miura, K., Higashijima, A., Shimada, T., Miura, S., Yamasaki, K., Abe, S., … Masuzaki, H. (2011). Clinical application of fetal sex determination using cell-free fetal DNA in pregnant carriers of X-linked genetic disorders. Journal of Human Genetics, 56(4), 296–299. https://doi.org/10.1038/jhg.2011.7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free